- Previous Close
1.9200 - Open
1.9160 - Bid --
- Ask --
- Day's Range
1.8400 - 1.9400 - 52 Week Range
1.4000 - 3.2800 - Volume
14,308 - Avg. Volume
35,126 - Market Cap (intraday)
19.136M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.20
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company's natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.
www.nflbiosciences.comRecent News: ALNFL.PA
View MorePerformance Overview: ALNFL.PA
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALNFL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALNFL.PA
View MoreValuation Measures
Market Cap
18.46M
Enterprise Value
14.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.07
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--